Compounds > oxazoles
Page last updated: 2024-08-21

oxazoles and Triple Negative Breast Neoplasms

oxazoles has been researched along with Triple Negative Breast Neoplasms in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (80.00)24.3611
2020's1 (20.00)2.80

Authors

AuthorsStudies
Alothaim, T; Charbonneau, M; Tang, X1
Cai, S; Cichewicz, RH; Glassman, M; McCowen, S; McHardy, SF; Mooberry, SL; Robles, AJ; Ruiz, F1
Bernier, C; Dankner, M; Gravel, M; Park, M; Petrecca, K; Roulston, A; Savage, P; Shore, GC; Siegel, PM; Soliman, A1
Buchholz, S; Engel, JB; Hohla, F; Inwald, EC; Klinkhammer-Schalke, M; Kwok, CW; Ortmann, O; Perez, R; Rick, FG; Schally, AV; Segerer, S; Seitz, S; Szalontay, L; Weber, F1
Emons, G; Girgert, R; Gründker, C; Hinsche, O1

Other Studies

5 other study(ies) available for oxazoles and Triple Negative Breast Neoplasms

ArticleYear
HDAC6 inhibitors sensitize non-mesenchymal triple-negative breast cancer cells to cysteine deprivation.
    Scientific reports, 2021, 05-26, Volume: 11, Issue:1

    Topics: Anilides; Carbamates; Cell Death; Cell Line, Tumor; Cysteine; Enzyme Activation; Epithelial Cells; Female; Gene Knockout Techniques; HEK293 Cells; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Homeostasis; Humans; Hydroxamic Acids; Indoles; Neoplasm Proteins; Oxazoles; Piperazines; Protein Kinase C; Small Molecule Libraries; Transcription, Genetic; Transcriptome; Triple Negative Breast Neoplasms; Zinc

2021
Structure-Activity Relationships of New Natural Product-Based Diaryloxazoles with Selective Activity against Androgen Receptor-Positive Breast Cancer Cells.
    Journal of medicinal chemistry, 2017, 11-22, Volume: 60, Issue:22

    Topics: Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Imidazoles; Mechanistic Target of Rapamycin Complex 1; Oxazoles; Proline; Proto-Oncogene Proteins c-akt; Receptors, Androgen; Rutaceae; Signal Transduction; Structure-Activity Relationship; Triple Negative Breast Neoplasms

2017
DZ-2384 has a superior preclinical profile to taxanes for the treatment of triple-negative breast cancer and is synergistic with anti-CTLA-4 immunotherapy.
    Anti-cancer drugs, 2018, Volume: 29, Issue:8

    Topics: Animals; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Brain; Cell Line, Tumor; CTLA-4 Antigen; Drug Synergism; Female; Humans; Lactams, Macrocyclic; Mice; Mice, Inbred BALB C; Mice, Inbred NOD; Mice, SCID; Neoplasm Metastasis; Oxazoles; Random Allocation; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays

2018
Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125.
    BMC cancer, 2014, Nov-19, Volume: 14

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Female; Gonadotropin-Releasing Hormone; Humans; Mice; Mice, Nude; Oxazoles; Receptors, LHRH; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays

2014
Estrogen receptor β selective agonists reduce invasiveness of triple-negative breast cancer cells.
    International journal of oncology, 2015, Volume: 46, Issue:2

    Topics: Cell Movement; Cell Proliferation; Coculture Techniques; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogens; Female; Flavanones; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Neoplasm Invasiveness; Oxazoles; Receptors, CXCR4; Triple Negative Breast Neoplasms

2015